HRP20161474T1 - Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave - Google Patents
Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave Download PDFInfo
- Publication number
- HRP20161474T1 HRP20161474T1 HRP20161474TT HRP20161474T HRP20161474T1 HR P20161474 T1 HRP20161474 T1 HR P20161474T1 HR P20161474T T HRP20161474T T HR P20161474TT HR P20161474 T HRP20161474 T HR P20161474T HR P20161474 T1 HRP20161474 T1 HR P20161474T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- cancer
- avpal
- phenylalanine
- variant
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 6
- 201000011510 cancer Diseases 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title 2
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-Phenylalanine Natural products OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- 229960005190 phenylalanine Drugs 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 claims 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 241000078013 Trichormus variabilis Species 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Farmaceutski sastav sadrži varijantu Anabaena variabilis fenilalanin amonij-liaze (AvPAL) i farmaceutski prihvatljivi nosač, pri čemu
(i) AvPAL varijanta ima slijed SEQ ID NO: 10, gdje na poziciji 565 AvPAL varijanta ima serinski ostatak; ili
(ii) AvPAL varijanta ima slijed SEQ ID NO: 11, gdje na pozicijama 503 i 565 AvPAL varijanta ima serinski ostatak; i
pri čemu farmaceutski prihvatljivi nosač sadrži stabilizator odabran iz grupe koja se sastoji od L-fenilalanina, trans-cimetne kiseline i benzojeve kiseline.
2. Farmaceutski sastav iz patentnog zahtjeva 1, pri čemu AvPAL ima slijed SEQ ID NO: 10.
3. Farmaceutski sastav iz patentnog zahtjeva 1, pri čemu AvPAL ima slijed SEQ ID NO: 11.
4. Farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 1-3, pri čemu je stabilizator L-fenilalanin.
5. Farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 1-3, pri čemu je stabilizator trans-cimetna kiselina.
6. Farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 1-3, pri čemu je stabilizator benzojeva kiselina.
7. Farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 1 do 6, pri čemu navedena AvPAL varijanta nadalje sadrži polimer topljiv u vodi.
8. Farmaceutski sastav iz patentnog zahtjeva 7, pri čemu je u vodi topljivi polimer polietilen glikol.
9. Farmaceutski sastav iz patentnog zahtjeva 8, pri čemu je omjer navedene AvPAL varijante i polietilen glikola oko 1:3 (1:3 AvPAL:PEG).
10. Farmaceutski sastav kako je definiran u patentnim zahtjevima 1 do 9 za uporabu u metodi liječenja raka.
11. Farmaceutski sastav za uporabu iz patentnog zahtjeva 10, pri čemu je rak odabran iz grupe koja se sastoji: raka pluća, raka mozga ili središnjeg živčanog sustava, raka kolona, raka prostate, raka bubrega, metastatskog melanoma, raka glave i vrata, raka jajnika, raka maternice, akutne mijeloične leukemije, akutne limfoblastične leukemije, mijeloma i pedijatrijskih maligniteta.
12. Farmaceutski sastav za uporabu iz patentnog zahtjeva 10, pri čemu je proliferacija i/ili preživljenje stanica izvedenih iz raka osjetljivo na restrikciju ili depleciju fenilalanina.
13. Farmaceutski sastav za uporabu iz patentnog zahtjeva 10, pri čemu navedena metoda nadalje obuhvaća davanje terapijskog agensa za rak, ili ciljanog terapijskog agensa za rak, ili dijetu bez proteina.
14. Farmaceutski sastav kako je definiran u patentnim zahtjevima 1 do 9 za uporabu u metodi smanjivanja koncentracije fenilalanina u krvi, serumu ili plazmi pacijenta.
15. Farmaceutski sastav za uporabu iz patentnih zahtjeva 10 do 14, pri čemu je farmaceutski sastav za smanjivanje koncentracije fenilalanina u krvi, serumu ili plazmi pacijenta od raspona ispod razine detekcije do manje od oko 20 µM, opcionalno do manje od oko 10 µM.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6612507P | 2007-08-17 | 2007-08-17 | |
| PCT/US2008/009765 WO2009025760A2 (en) | 2007-08-17 | 2008-08-15 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| EP08795357.6A EP2175875B1 (en) | 2007-08-17 | 2008-08-15 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161474T1 true HRP20161474T1 (hr) | 2016-12-30 |
Family
ID=40363135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161474TT HRP20161474T1 (hr) | 2007-08-17 | 2016-11-08 | Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7537923B2 (hr) |
| EP (1) | EP2175875B1 (hr) |
| JP (1) | JP5584120B2 (hr) |
| CN (1) | CN101803492B (hr) |
| AR (2) | AR067972A1 (hr) |
| AU (1) | AU2008289549B2 (hr) |
| BR (2) | BR122018072594B8 (hr) |
| CA (1) | CA2687028C (hr) |
| CL (1) | CL2008002390A1 (hr) |
| CY (1) | CY1118222T1 (hr) |
| DK (1) | DK2175875T3 (hr) |
| ES (1) | ES2602618T3 (hr) |
| HR (1) | HRP20161474T1 (hr) |
| HU (1) | HUE029510T4 (hr) |
| LT (1) | LT2175875T (hr) |
| MX (1) | MX2009012261A (hr) |
| PE (1) | PE20090605A1 (hr) |
| PL (1) | PL2175875T3 (hr) |
| PT (1) | PT2175875T (hr) |
| RU (2) | RU2553343C2 (hr) |
| SI (1) | SI2175875T1 (hr) |
| TW (1) | TWI418787B (hr) |
| WO (1) | WO2009025760A2 (hr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| EP3381445B1 (en) * | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
| US20110201022A1 (en) * | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| WO2011078667A2 (en) | 2009-12-22 | 2011-06-30 | Dsm Ip Assets B.V. | Method of finding a biocatalyst having ammonia lyase activity |
| CA2782444C (en) | 2010-02-04 | 2018-10-23 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof |
| US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| US20150246083A1 (en) * | 2012-07-27 | 2015-09-03 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| WO2014172541A2 (en) | 2013-04-18 | 2014-10-23 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| CA2944492A1 (en) | 2014-04-01 | 2015-10-08 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| DK3145536T3 (da) | 2014-04-16 | 2022-01-03 | Codexis Inc | Modificeret tyrosinammoniaklyase |
| US9789169B2 (en) | 2014-04-29 | 2017-10-17 | Bio-Cancer Treatment International Limited | Methods and compositions for modulating the immune system with arginase I |
| WO2016008886A1 (en) * | 2014-07-14 | 2016-01-21 | Danmarks Tekniske Universitet | Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity |
| PT3237621T (pt) | 2014-12-22 | 2023-07-20 | Codexis Inc | Variantes da alfa-galactosidase humana |
| EP3491008A2 (en) | 2016-07-26 | 2019-06-05 | BioMarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
| IT201600086488A1 (it) * | 2016-08-22 | 2018-02-22 | St Microelectronics Srl | Dispositivo a semiconduttore e corrispondente procedimento |
| MY196740A (en) * | 2017-02-13 | 2023-05-03 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| EP3790627A2 (en) | 2018-05-09 | 2021-03-17 | BioMarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| EP3807409A4 (en) | 2018-06-12 | 2022-08-03 | Codexis, Inc. | MODIFIED TYROSINE AMMONIA-LYASE |
| AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| US11427813B2 (en) | 2018-12-20 | 2022-08-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| JP2022545718A (ja) | 2019-08-30 | 2022-10-28 | コデクシス， インコーポレイテッド | 操作されたリパーゼ改変体 |
| CA3165484A1 (en) | 2019-12-20 | 2021-06-24 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
| AR122409A1 (es) | 2020-04-03 | 2022-09-07 | Biomarin Pharm Inc | Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas |
| MX2023002421A (es) | 2020-08-28 | 2023-05-18 | Codexis Inc | Variantes de amilasa modificadas geneticamente. |
| JP2023539632A (ja) | 2020-08-28 | 2023-09-15 | コデクシス， インコーポレイテッド | 操作されたプロテアーゼバリアント |
| EP4341394A1 (en) | 2021-05-19 | 2024-03-27 | BioMarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5212939A (en) * | 1991-12-04 | 1993-05-25 | Pratt Jr John M | Marine mooring swivel fitting |
| PT668933E (pt) | 1992-11-19 | 2003-02-28 | Anticancer Inc | Utilizacao de metioninase como agente anti-tumor em qimioterapia anti-metionina |
| AU3235893A (en) | 1992-12-04 | 1994-07-04 | Me Medical Enzymes Ag | Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| DK75593D0 (hr) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| GB9418092D0 (en) * | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| KR0164757B1 (ko) * | 1995-06-13 | 1999-01-15 | 김광호 | 공조장치의 살균집진장치와 그 방법 |
| DK1568772T3 (da) | 1995-09-21 | 2010-10-18 | Genentech Inc | Varianter af humant væksthormon |
| CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| JP4812167B2 (ja) | 1999-02-12 | 2011-11-09 | モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド | 薬物輸送用マトリックス、ならびにその作成方法および使用方法 |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| WO2001079469A2 (en) | 2000-04-14 | 2001-10-25 | University Of South Carolina Research Foundation | Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| US6967097B2 (en) * | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| US6939941B2 (en) * | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
| KR20040088538A (ko) | 2002-02-26 | 2004-10-16 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 유전 인자의 재조합 방법 |
| US20080124275A1 (en) | 2002-11-14 | 2008-05-29 | The Scripps Research Institute | Crystalline Form of Fatty Acid Amide Hydrolase (Faah) |
| US7553653B2 (en) | 2004-09-17 | 2009-06-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| CA2614769A1 (en) | 2005-03-10 | 2006-09-21 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| DE102006032167B4 (de) | 2006-07-12 | 2014-11-27 | Evonik Degussa Gmbh | Verfahren zur Herstellung von Triallylisocyanurat (TAIC) |
| WO2008069958A2 (en) | 2006-12-01 | 2008-06-12 | The Salk Institute For Biological Studies | Substrate switched ammonia lyases and mutases |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| US20110201022A1 (en) | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
-
2008
- 2008-04-22 US US12/107,736 patent/US7537923B2/en active Active
- 2008-04-22 US US12/107,731 patent/US7560263B2/en active Active
- 2008-08-14 CL CL2008002390A patent/CL2008002390A1/es unknown
- 2008-08-15 RU RU2012134838/15A patent/RU2553343C2/ru active
- 2008-08-15 TW TW097131325A patent/TWI418787B/zh active
- 2008-08-15 PL PL08795357T patent/PL2175875T3/pl unknown
- 2008-08-15 SI SI200831703A patent/SI2175875T1/sl unknown
- 2008-08-15 CA CA2687028A patent/CA2687028C/en active Active
- 2008-08-15 MX MX2009012261A patent/MX2009012261A/es active IP Right Grant
- 2008-08-15 JP JP2010521043A patent/JP5584120B2/ja active Active
- 2008-08-15 RU RU2009141987/15A patent/RU2009141987A/ru not_active Application Discontinuation
- 2008-08-15 EP EP08795357.6A patent/EP2175875B1/en active Active
- 2008-08-15 CN CN200880016488.XA patent/CN101803492B/zh active Active
- 2008-08-15 DK DK08795357.6T patent/DK2175875T3/en active
- 2008-08-15 BR BR122018072594A patent/BR122018072594B8/pt active IP Right Grant
- 2008-08-15 AR ARP080103596A patent/AR067972A1/es not_active Application Discontinuation
- 2008-08-15 ES ES08795357.6T patent/ES2602618T3/es active Active
- 2008-08-15 LT LTEP08795357.6T patent/LT2175875T/lt unknown
- 2008-08-15 PE PE2008001395A patent/PE20090605A1/es active IP Right Grant
- 2008-08-15 PT PT87953576T patent/PT2175875T/pt unknown
- 2008-08-15 HU HUE08795357A patent/HUE029510T4/en unknown
- 2008-08-15 WO PCT/US2008/009765 patent/WO2009025760A2/en active Application Filing
- 2008-08-15 BR BRPI0811589A patent/BRPI0811589B8/pt active IP Right Grant
- 2008-08-15 AU AU2008289549A patent/AU2008289549B2/en active Active
-
2009
- 2009-04-09 US US12/421,557 patent/US7790433B2/en active Active
-
2010
- 2010-07-09 US US12/833,911 patent/US20100278802A1/en not_active Abandoned
-
2016
- 2016-11-08 HR HRP20161474TT patent/HRP20161474T1/hr unknown
- 2016-11-10 CY CY20161101163T patent/CY1118222T1/el unknown
-
2019
- 2019-01-24 AR ARP190100158A patent/AR117389A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161474T1 (hr) | Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave | |
| TWI761305B (zh) | 抑制Ｈｉｆ２α基因表現之組合物及方法 | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| Mauger et al. | Characteristics and metabolism of alpha 1 adrenergic receptors in a nonfusing muscle cell line. | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201806134SA (en) | Oncolytic viral vectors and uses thereof | |
| SG11201908012SA (en) | Cyclic sulfamide compounds and methods of using same | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201804148TA (en) | Rsv f protein mutants | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201408807YA (en) | Tm-enhanced blocking oligonucleotides and baits for improved target enrichment and reduced off-target selection | |
| Dahut et al. | Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. | |
| JP2014506135A5 (hr) | ||
| CA2579523A1 (en) | Atad3a-binding molecules for treatment, detection and prevention of cancer | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| UA77945C2 (en) | Use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders (variants), pharmaceutical composition (variants) | |
| JP2010536759A5 (hr) | ||
| SG11201901273TA (en) | Blood plasma fractions as a treatment for aging-associated cognitive disorders | |
| WO2009065028A3 (en) | Brca1-based breast or ovarian cancer prevention agents and methods of use | |
| US20110306562A1 (en) | Antisense EGFRAS Guanidinium Peptide Nucleic Acid (GPNA) Oligonucleotides as Antitumor Agents | |
| WO2009114809A1 (en) | Therapies for cancer using isotopically substituted lysine | |
| SG11201407599SA (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| BR0209452A (pt) | Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto | |
| SG11201805142RA (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |